Articles From: Publicis to buy Sapient for $3.7 billion to Arena Pharmaceuticals Reports Positive Results from Phase 1b Clinical Trial Evaluating APD334 for the Treatment of Autoimmune Diseases

By Inti Landauro and Ruth Bender PARIS --
Sign-up for Publicis to buy Sapient for $3.7 billion investment picks
By Inti Landauro PARIS--
Sign-up for GDF Suez to Name Judith Hartmann as Chief Financial Officer investment picks
By Inti Landauro PARIS--Charlie Hebdo is planning a bumper print run of one million copies for its next edition, in a defiant response to the brutal attack on its offices that killed the top editor and seven staffers and contributors.
Sign-up for Charlie Hebdo to Continue Publishing in Wake of Attack -- Update investment picks
By Inti Landauro PARIS--France's largest retailer Carrefour SA (CA.FR) said Friday its sales grew faster than expected in the fourth quarter of 2014, boosted by its business in France, where the company is regaining ground, and in Brazil.
Sign-up for Carrefour Says 4Q Sales Rose, Lifted by France, Brazil investment picks
By Inti Landauro PARIS--French engineering group Alstom SA said Wednesday that third-quarter sales rose 11% as it delivered more rolling stock in France, Germany, Italy, Switzerland and Dubai.
Sign-up for Alstom Sales Lifted by Rising Deliveries investment picks
By Inti Landauro PARIS--French police on Wednesday detained a controversial French stand-up comedian over online comments apparently comparing himself to one of the gunmen in the attacks that stunned France last week and left 17 dead.
Sign-up for French Comic Detained Over Charlie Hebdo Comments--Update investment picks
By Inti Landauro PARIS--French retailer Groupe Casino (CO.FR) said Thursday that its sales dipped in 2014 as a result of adverse exchange rate in foreign markets.
Sign-up for Casino 2014 Sales Dip, Hurt by Exchange Rate investment picks
By Inti Landauro Technip rallies 8.8% after dropping CGG bid PARIS--French oil-service company Technip SA on Sunday said it has dropped plans to acquire peer CGG after talks on a potential merger failed.
Sign-up for Technip drops EUR1.46 billion bid for CGG investment picks
By Inti LandauroMerger move comes amid consolidation in oil-services industry PARIS --
Sign-up for Technip makes $1.83 billion takeover approach to CGG investment picks
New Store Underscores Deckers Brands' Commitment to Omni-Channel Consumer Experience GOLETA, Calif.
Sign-up for UGG® Opens First High-Tech Concept Store In Washington, D.C. Area investment picks
Universal Electronics Inc. (UEI), (NASDAQ: UEIC) reported financial results for the three and nine months ended September 30, 2014.
Sign-up for Universal Electronics Reports Third Quarter 2014 Financial Results investment picks
Lighting Science Group Corporation announced that it has received $13.0 million in preferred stock financing from Serengeti Asset Management.
Sign-up for Lighting Science Receives $13.0 Million Equity Investment to Fund Growth investment picks
Lighting Science Group Corporation (OTCQB: LSCG) is pleased to announce the launch of the new Vintage™ Filament Series of LED lamps.
Sign-up for Lighting Science Group Unveils Much Anticipated Vintage Filament Series LED Lamps investment picks
Advanced Technology Will Facilitate an Enriched Learning Environment and Help Oakland Deliver Quality Education Across More Than 100 Sites OAKLAND, Calif.
Sign-up for Oakland Unified School District Selects Comcast Business Ethernet Services to Help Propel Students and Faculty into the Future investment picks
U.S. Global Investors, Inc. ( Nasdaq: GROW ), a boutique registered investment advisory firm specializing in natural resources, emerging markets, domestic equities and municipal bonds, announces that three of the mutual funds it manages will pay 2014 income dividend or capital gains distributions.
Sign-up for U.S. Global Investors Funds to Pay Year-End Distributions investment picks SAN FRANCISCO, CA --
Sign-up for TIBCO Brings Powerful New Ease-of-Use Enhancements to Fast Data Capabilities investment picks
- AbbVie Presents for the First Time Results from the Venetoclax Phase 2 Program in Acute Myelogenous Leukemia - Study Evaluated Preliminary Efficacy of Venetoclax in 32 Patients with Relapsed/Refractory Acute Myelogenous Leukemia and as Frontline Therapy in Patients Unfit for Intensive Treatment NORTH CHICAGO, Ill.
Sign-up for AbbVie Presents Results from Phase 2 Study of Investigational Compound Venetoclax (ABT-199/GDC-0199) in Acute Myelogenous Leukemia at the 56th American Society of Hematology Annual Meeting investment picks
- Data include results from a Phase 1 study of ABT-414 as monotherapy and in combination with radiation and/or chemotherapy in patients with newly diagnosed and recurrent/unresectable glioblastoma multiforme - AbbVie will initiate a randomized Phase 2 trial of ABT-414 in patients with glioblastoma multiforme NORTH CHICAGO, Ill.
Sign-up for AbbVie Presents Results from Study of ABT-414 in Patients with Glioblastoma Multiforme at the 19th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology investment picks
Data from 13 accepted abstracts include: - New Results from a Phase 2 Study of Venetoclax (formerly ABT-199/GDC-0199) in Patients with Acute Myelogenous Leukemia (AML) - Several Studies of Elotuzumab in Patients with Multiple Myeloma, Including Final Results from a Phase 1b/2 Study - Results from Phase 1 studies of Duvelisib in Patients with Chronic Lymphocytic Leukemia NORTH CHICAGO, Ill.
Sign-up for AbbVie to Present Data on Investigational Oncology Compounds at the 56th American Society of Hematology Annual Meeting investment picks PALO ALTO, CA --
Sign-up for HP Unveils Future of 3D Printing and Immersive Computing as Part of Blended Reality Vision investment picks
By Ira Iosebashvili, James Ramage and Alexandra Wexler When Simon Mammon turned on his computer at 4:30 a.m. Thursday to check his trading portfolio, the owner of the Simon Sips cafe in Midtown Manhattan was just in time to see his bet on the Swiss franc SHYimplode.
Sign-up for Swiss Franc Bets Turned on a Dime investment picks
By Ira Iosebashvili And Ese Erheriene Copper prices suffered their biggest one-day decline in over three years Wednesday, reflecting mounting concerns among investors about the health of the world economy.
Sign-up for Copper Prices Suffer Biggest One-Day Decline in Over Three Years investment picks
By Isabella Steger and Fiona Law Masked assailants attacked the residence of the publisher of Hong Kong's most pro-democracy newspaper and the publication's offices on Monday, the latest in a string of attacks against Hong Kong media mogul Jimmy Lai weeks after his arrest for his involvement in pro-democracy protests in the city.
Sign-up for Petrol bombs thrown at Beijing critic Jimmy Lai's home, office investment picks
By Isabella Zhong Already battered commodities prices suffered yet another blow as the U.S. dollar soared to its highest level in more than a decade on Friday.
Sign-up for Copper Sees Red on Surplus Metal Fears -- Barron's Asia investment picks
Aggressive pursuit of a bigger share of China's online shopping market may payoff and lift the stock 25%. By Isabella Zhong For bullish supporters of, the news earlier this week that the online retailer would be included in the MSCI China Index is one more reason to buy the stock.
Sign-up for Chases Growth First, Profits Second -- Barron's Asia investment picks
By Isabella Zhong Haitong Securities among casualties as Beijing tightens rules on financing trades.
Sign-up for China Brokers Smashed in Margin Crackdown -- Barron's Asia investment picks
By Isabella Zhong Li Ka-shing once said "vision is perhaps our greatest strength." And the vision that the 86-year-old tycoon has for his sprawling business empire is a sparkling new corporate structure that separates the real estate and non-real estate assets of his two flagship conglomerates, Cheung Kong Holdings (0001.HK) and Hutchison Whampoa (0013.HK). In a nutshell, Cheung Kong and Hutchison Whampoa, in which Cheung Kong holds a 49.97% stake, are to be merged into a new Cayman Island-based company called CK Hutchison Holdings.
Sign-up for Li Ka-shing's Shakeup Applauded by Investors -- Barron's Asia investment picks
State Street Global Advisors (SSGA) announced today the appointment of Rory Tobin as head of European distribution.
Sign-up for State Street Global Advisors Appoints Head of European Distribution investment picks
- Trial results show novel S1P1 modulator produced strong, dose-dependent lymphocyte lowering - - No clinically significant safety findings relative to heart, liver or pulmonary function - SAN DIEGO , Jan.
Sign-up for Arena Pharmaceuticals Reports Positive Results from Phase 1b Clinical Trial Evaluating APD334 for the Treatment of Autoimmune Diseases investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar

Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Publicis to buy Sapient for $3.7 billion to Arena Pharmaceuticals Reports Positive Results from Phase 1b Clinical Trial Evaluating APD334 for the Treatment of Autoimmune Diseases
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent